10-Q: Nordicus Partners Corporation Reports Increased Net Loss in Q2 2025 Amidst Acquisition and Operational Changes

Nordicus Partners Corporation reported a significant increase in net loss for the second quarter of 2025, driven by increased operating expenses and the impact of recent acquisitions.

Summary

• Nordicus Partners Corporation reported a net loss of $500,785 for the three months ended September 30, 2024, compared to a net loss of $98,790 for the same period in 2023.
• The company's net loss for the six months ended September 30, 2024, was $758,954, a significant increase from the $139,086 loss in the same period of 2023.
• Operating expenses increased significantly, with officer compensation rising to $98,546 for the six months ended September 30, 2024, from $57,593 in the prior year.
• General and administrative expenses also saw a substantial increase, reaching $104,099 for the six months ended September 30, 2024, compared to $14,084 in the same period of 2023.
• The company completed the acquisition of Orocidin A/S on May 13, 2024, issuing 3,800,000 shares of common stock in the process.
• A 1-for-10 reverse stock split was effectuated on November 8, 2024.
• The company's cash balance decreased to $46,131 as of September 30, 2024, from $49,933 as of March 31, 2024.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the significant increase in net loss, rising operating expenses, and concerns about the company's ability to continue as a going concern. While there are some positive developments, such as the acquisition of Orocidin A/S, the overall financial picture is concerning.

Positives

• The company successfully acquired a 95% stake in Orocidin A/S, expanding its portfolio in the biopharmaceutical sector.
• The company raised $254,000 through the exercise of warrants by GK Partners.
• The company has a comprehensive network of business partners and associates across Europe and the U.S.

Negatives

• The company experienced a significant increase in net loss for both the three and six month periods ending September 30, 2024.
• Operating expenses, particularly officer compensation and general and administrative costs, increased substantially.
• The company's cash balance decreased during the reporting period.
• The company has an accumulated deficit of $44,642,481 as of September 30, 2024.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Risks

• The company's ability to continue as a going concern is dependent on generating profitable operations or obtaining necessary financing.
• The company's accumulated deficit and ongoing losses raise concerns about its financial stability.
• The company's disclosure controls and procedures are not effective, which could lead to inaccurate financial reporting.
• The company's investment in Mag Mile Capital, Inc. is subject to changes and fluctuations based on their business activities and their ability to trade in the future.

Future Outlook

The company intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants. The company is also focused on assisting Nordic companies in establishing themselves in the U.S. market and is exploring various business opportunities.

Management Comments

• Management intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants.
• Management believes the company's core competencies lie in assisting Danish as well as other Nordic and international companies in different areas of corporate finance activities.
• Management is focused on assisting the right Nordic companies realize their growth strategy.

Industry Context

The company operates in the financial consulting and biopharmaceutical sectors, focusing on assisting Nordic companies in the U.S. market. The acquisition of Orocidin A/S aligns with the company's strategy to expand its presence in the life sciences and healthcare industries. The company also acts as a business incubator, providing support resources for companies transitioning to the U.S. market.

Comparison to Industry Standards

• The company's financial performance is significantly below industry standards for profitability, with substantial net losses and increasing operating expenses.
• Compared to established financial consulting firms, Nordicus's revenue is minimal, indicating a need for significant growth in client acquisition and service delivery.
• The company's acquisition of Orocidin A/S is a strategic move to enter the biopharmaceutical sector, but the financial impact of this acquisition is yet to be seen.
• The company's cash position is weak compared to industry benchmarks, raising concerns about its ability to fund operations and growth initiatives.
• The company's internal control deficiencies are a significant concern, as they could lead to inaccurate financial reporting and potential regulatory issues. This is not in line with industry best practices for public companies.

Management Changes

Corporate Governance

Related Party Transactions

• Mr. Tom Glasner Larsen is an affiliate of GK Partners and was a member of our board of directors until June 9, 2023.
• Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services.
• Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and was amended to $120,000 per year on April 8, 2024.
• Our consulting agreement with Bennett Yankowitz, our chief financial officer and a member of our board of directors, provided for a base salary of $36,000 per year, commencing April 1, 2023, and was amended to $60,000 per year on April 8, 2024.
• During the six months ended September 30, 2024, a related party forgave their payable of $13,886.

Stakeholder Impact

• Shareholders are negatively impacted by the increased net loss and the company's going concern risk.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers may be affected by the company's ability to provide services if financial difficulties persist.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants.
• The company will continue to focus on assisting Nordic companies in establishing themselves in the U.S. market.
• The company will work to improve its internal controls and procedures.
• The company will integrate Orocidin A/S into its operations.

Key Dates

Keywords

Nordicus Partners Corporation, Orocidin A/S, financial results, net loss, operating expenses, acquisition, reverse stock split, biopharmaceutical, stock issuance, warrants, going concern